DoD Melanoma, Idea Award | W81XWH 19 MRP IA

Opportunity Information: Apply for W81XWH 19 MRP IA

The DoD Melanoma Idea Award (FY19), administered by the Department of Defense through the U.S. Army Medical Research Acquisition Activity (USAMRAA), was a discretionary research funding opportunity designed to push melanoma science in genuinely new directions. It specifically targeted bold, untested, and potentially high-impact ideas rather than proposals that extend an existing, already productive research line. The overall intent was to accelerate advancements that could improve melanoma knowledge, patient care practices, and treatment options within the Military Health System, with clear relevance to active duty Service members, Veterans, other military beneficiaries, and, by extension, the broader public.

A defining feature of this award was its emphasis on innovation and risk. Applicants were expected to propose high-risk/potentially high-reward concepts, including new theories, novel methods, fresh paradigms, or approaches that challenge prevailing assumptions in melanoma research. The program language makes it clear that it was not meant to fund incremental work, the next logical step in a well-established project, or routine extensions such as simply moving an established model from one cancer type to melanoma. In other words, the bar for novelty was high, and the value proposition needed to be rooted in creativity and the possibility of opening up new lines of investigation.

At the project level, the solicitation required a well-formulated and testable novel hypothesis supported by strong scientific rationale and a sound study design. Even though the award welcomed untested concepts, it still expected applicants to demonstrate that the idea was scientifically grounded and that the research plan could credibly generate interpretable results. This reflects a common balance in "idea" style awards: encouraging unconventional thinking while still requiring methodological rigor and a clear pathway for evaluating the hypothesis.

The opportunity also included explicit topic boundaries that applicants had to respect. The FY19 MRP did not seek research focused on established macrometastatic melanoma, did not want studies modeling metastatic disease using established cell lines, and did not support projects centered on treating macrometastatic disease. In addition, studies involving non-melanoma skin cancers were not allowed. These restrictions signal that the program was aiming funding toward earlier-stage biology, prevention, detection, or other innovative angles within melanoma, rather than concentrating on late-stage metastatic disease paradigms that may already have substantial research momentum or established model systems.

From an administrative standpoint, the funding opportunity was listed as W81XWH-19-MRP-IA under CFDA 12.420, with awards anticipated in the form of grants and/or cooperative agreements. Eligibility was described as unrestricted, meaning a wide range of organizations could apply (subject to any additional eligibility clarifications in the full announcement). The opportunity was posted on May 16, 2019, with an original closing date of October 23, 2019, and it projected approximately eight awards. The award ceiling was listed as 0, which typically indicates that the maximum funding level was not specified in that particular data field and would need to be confirmed in the full program announcement or related guidance.

Overall, this grant opportunity can be summarized as a competitive DoD mechanism intended to seed daring, non-incremental melanoma research ideas that could reshape how the field thinks about key problems, while explicitly excluding non-melanoma skin cancers and steering away from established macrometastatic disease research and common metastatic modeling approaches.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Melanoma, Idea Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on May 16, 2019.
• Applicants must submit their applications by Oct 23, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 8 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 19 MRP IA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: